About Us



Harry Rosen (BA, LLB)
Chief Executive Officer


Mr Rosen is one of the founders of Betatene Limited and Denehurst Ltd, two formerly ASX-listed companies which commercialised significant research and development.  Betatene is the world's largest producer of natural beta carotene.  After the purchase of Betatene Limited by Henkel Corporation, Mr Rosen served as Vice President, Corporate Development.  As a Vice President of Henkel Corporation, he worked for a number of years in the US in the nutrition and health care industries.

Mr Rosen has consulted to many technology companies assisting them with the commercialisation of new technologies.  He has had significant experience in the areas of seed capital raising, stock exchange listings, taxation and corporate law.  Mr Rosen graduated from the Australian National University (BA-Psychology) and University of Melbourne (LLB).


Paul Gavin (BSc (Hons), PhD)
Chief Scientific Officer


Dr Gavin is responsible for the global coordination and management of the company’s pre-clinical and clinical research.

Since joining the Company in 2002, Dr Gavin has developed opportunities in both the Company’s pharmaceutical and nutraceutical divisions such as transdermal drug delivery systems and drug enhancement platforms for chronic pain management.  He is an inventor of the TPM platform technology for transdermal delivery, and has managed its development from discovery to clinical development with a range of products.

Dr Gavin holds a Bachelor of Science (Hons) and a PhD in Biochemistry & Molecular Biology from Monash University, Melbourne.  He is experienced in many aspects of academic and commercial research and development and has published in peer journals.

          Anna Legg (BEc, Dip Law)
Chief Financial Officer


Ms Legg joined Phosphagenics in January 2013.  She has over five years experience in financial management in government, private and public companies.  She has been involved in establishing international entities covering their tax, legal and funding requirements.

Her particular strengths include statutory reporting, system development and financial modelling.

          Divyang Butala (BSc (Hons), PhD)
Vice President, Bioanalytical and CMC


Dr Butala joined the Company in 2009 and is responsible for the management of the Bioanalytical and CMC Department.  He is also responsible for the smooth scale-up of products from the Chemistry laboratory to the Hallmarc manufacturing facility where the process is validated and locked-in.

He has more than 20 years experience in Pharmaceutical industry - including R&D/QC Laboratory management, process development and scale-up of new drug candidates for clinical trials in Australia and overseas.  During this period Dr Butala gained considerable expertise in preparing technical data packages for TMF, DMF and IND submission to TGA and FDA.

          Mahmoud El-Tamimy (BPharm, PhD)
Vice President, Innovation and Development


Dr El-Tamimy joined the Company in 2007 from Monash University after working in formulation and development for Acrux Ltd.  He graduated in 1993 with a Bachelor of Pharmacy and has since completed his PhD in pharmaceutical development and industrial pharmacy.  He has 18 years of experience locally and internationally and has been involved in numerous projects with major global pharmaceutical companies.  His expertise has been required from the initial in vitro and in vivo studies through to late stage clinical trials.

At Phosphagenics Dr El-Tamimy is responsible for formulation development, clinical trial manufacturing and generation of new IP.  He had an instrumental role in design and development of the Oxycodone TPM patch.

          Alex Stojanovic (PhD) 
Vice President, Business Development & Commercial Operations

Dr Stojanovic joined Phosphagenics in February 2014. He has 10 years of broad commercial experience, during which he has advised, worked for, or partnered with, more than 30 pharmaceutical, biotech and medical device companies on various aspects of business development, commercialization, marketing, pricing, market access and corporate strategy.

Dr Stojanovic served as Senior Director of Global New Compound Marketing at Grunenthal GmbH, managing the global commercial development of two pipeline pain molecules. He received a PhD in Pharmacology & Toxicology from Dartmouth College (USA) and BS degrees in Chemistry and Cell & Structural Biology from the University of Illinois (USA).